Statement: There was only one patient cohort in the primary trial.
Primary_evidence: Adverse Events 1:   Total: 29/30 (96.67%)   Febrile neutropenia  [1]3/30 (10.00%)   Lymphatics 1/30 (3.33%)   Diarrhea (without colostomy) 5/30 (16.67%)   Abdominal pain or cramping 2/30 (6.67%)   Colitis 1/30 (3.33%)   Dehydration 1/30 (3.33%)   Nausea 1/30 (3.33%)   Stomatitis/pharyngitis (oral/pharyngeal/mucositis) 1/30 (3.33%)   Vomiting 1/30 (3.33%) Adverse Events 2: